Work for Fulcrum Therapeutics, Inc.?

Claim Your Profile

Fulcrum Therapeutics, Inc. Logo Image

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. has reached its limit for free report views.

About Fulcrum Therapeutics, Inc.

51-200 Employees
Based in Cambridge, Massachusetts

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates filing an IND in the third quarter with initiation of a clinical trial in the fourth quarter of 2020 with FTX-6058 for the treatment of sickle cell disease.

Ticker:
FULC
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol